Kalıtsal Meme Kanserinde Genetik Mutasyonlar ve Risk Azaltıcı Cerrahi Yaklaşımlar

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71. https://doi.org/10.3322/caac.21660.

Breast Cancer Risk Genes — Association Analysis in More than 113,000 Women. New England Journal of Medicine 2021;384. https://doi.org/10.1056/nejmoa1913948.

Daly MB, Pilarski R, Yurgelun M, et al. Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate. NCCN Clinical Practice Guidelines in Oncology 2023;3.2023.

Sessa C, Balmaña J, Bober SL, et al. Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline ☆. Annals of Oncology 2023;34. https://doi.org/10.1016/j.annonc.2022.10.004.

Ajaz S, Zaidi SEZe, Ali S, et al. Germline Mutation Analysis in Sporadic Breast Cancer Cases With Clinical Correlations. Front Genet 2022;13. https://doi.org/10.3389/fgene.2022.820610.

Valencia OM, Samuel SE, Viscusi RK, et al. The role of genetic testing in patients with breast cancer a review. JAMA Surg 2017;152. https://doi.org/10.1001/jamasurg.2017.0552.

Tung N, Battelli C, Allen B, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2015;121. https://doi.org/10.1002/cncr.29010.

Prof. Dr. Vahit ÖZMEN. Meme Kanseri Korunma, Tarama, Tanı, Tedavi ve İzlem Klinik Rehberi. vol. 2. 2nd ed. 2024.

Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics in Medicine 2015;17. https://doi.org/10.1038/gim.2015.30.

Wolmark N, Dunn BK. The role of tamoxifen in breast cancer prevention: Issues sparked by the NSABP breast cancer prevention trial (P-1). Ann. N. Y. Acad. Sci., vol. 949, 2001. https://doi.org/10.1111/j.1749-6632.2001.tb04007.x.

Clarke MJ. WITHDRAWN: Tamoxifen for early breast cancer. Cochrane Database Syst Rev 2008.

Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [see comments]. JAMA 1999;281.

Vogel VG. The NSABP Study of Tamoxifen and Raloxifene (STAR) trial. Expert Rev Anticancer Ther 2009;9. https://doi.org/10.1586/14737140.9.1.51.

Cuzick J, Sestak I, Forbes JF, et al. Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial. The Lancet 2020;395. https://doi.org/10.1016/S0140-6736(19)32955-1.

Li X, You R, Wang X, et al. Effectiveness of prophylactic surgeries in BRCA1 or BRCA2 mutation carriers: A meta-analysis and systematic review. Clinical Cancer Research 2016;22. https://doi.org/10.1158/1078-0432.CCR-15-1465.

Giannakeas V, Narod SA. The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy. Breast Cancer Res Treat 2018;167. https://doi.org/10.1007/s10549-017-4476-1.

Carbine NE, Lostumbo L, Wallace J, et al. Risk-reducing mastectomy for the prevention of primary breast cancer. Cochrane Database of Systematic Reviews 2018;2018. https://doi.org/10.1002/14651858.CD002748.pub4.

Murphy BL, Yi M, Arun BK, et al. Contralateral Risk-Reducing Mastectomy in Breast Cancer Patients Who Undergo Multigene Panel Testing. Ann Surg Oncol 2020;27. https://doi.org/10.1245/s10434-020-08889-6.

Wang Y, Song Z, Zhang S, et al. Risk-reducing salpingo-oophorectomy and breast cancer risk in BRCA1 or BRCA2 mutation carriers: A systematic review and meta-analysis. European Journal of Surgical Oncology 2022;48. https://doi.org/10.1016/j.ejso.2022.02.019.

Garstka M, Henriquez A, Kelly BN, et al. How Protective are Nipple-Sparing Prophylactic Mastectomies in BRCA1 and BRCA2 Mutation Carriers? Ann Surg Oncol 2021;28. https://doi.org/10.1245/s10434-021-10445-9.

Kelly BN, Faulkner HR, Smith BL, et al. Nipple-Sparing Mastectomy versus Skin-Sparing Mastectomy: Does Saving the Nipple Impact Short- and Long-Term Patient Satisfaction? Ann Surg Oncol 2022;29. https://doi.org/10.1245/s10434-021-10767-8.

Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Annals of Oncology 2020;31. https://doi.org/10.1016/j.annonc.2020.08.2098.

Geyer CE, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Annals of Oncology 2022;33. https://doi.org/10.1016/j.annonc.2022.09.159.

Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. New England Journal of Medicine 2022;387. https://doi.org/10.1056/nejmoa2203690.

Yala A, Mikhael PG, Strand F, et al. Multi-Institutional Validation of a Mammography-Based Breast Cancer Risk Model. Journal of Clinical Oncology 2022;40. https://doi.org/10.1200/JCO.21.01337.